Table 3 Estimates of mean survival (months) based on studies of patients with squamous histology

REVEL

Ram + Doc (157)

Plac + Doc (171)

 RMS [95% CI]

to 24 mos

10.89 [19.65–12.13]

9.92 [8.75–11.10]

0.96 [− 0.75–2.67]

 Mean total OS

R_mSext

12.04

11.87

0.17

 Mean total OS

Weibull [95% CI]

11.91 [10.01–14.29]

11.08 [9.31–13.29]

0.83 [−2.09–3.75]

 Mean total OS

Weibull formula

11.90

11.07

0.83

Lux-lung 8

Afatanib (398)

Erlotinib (397)

 RMS [95% CI]

to 24 mos

10.48 [9.67–11.28]

8.95 [8.23–9.67]

1.52 [0.44–2.61]

 Mean total OS

R_mSext

10.98

9.87

1.11

 Mean total OS

Weibull [95% CI]

11.46 [10.19–12.94]

9.32 [8.39–10.37]

2.14 [0.45–3.83]

 Mean total OS

Weibull formula

11.35

9.41

1.94

LUME LUNG-1

Nin + Doc (276)

Docetaxel (279)

 RMS [95% CI]

to 24 mos

10.65 [9.79–11.52]

10.14 [9.26–11.02]

0.51 [−0.72–1.75]

 Mean total OS

R_mSext

11.76

12.19

−0.43

 Mean total OS

Weibull [95% CI]

11.67 [10.42–13.07]

11.73 [10.31–13.38]

−0.06 [−2.09–1.97]

 Mean total OS

Weibull formula

11.67

11.72

−0.06

Checkmate_017

Nivolumab (135)

Docetaxel (137)

 RMS [95% CI]

to 24 mos

11.94 [10.48–13.39]

8.33 [7.15–9.52]

3.61 [1.73–5.48]

 Mean total OS

R_mSext

17.14

9.76

7.37

 Mean total OS

Weibull [95% CI]

15.92 [12.79–19.94]

9.41 [7.78–11.41]

6.51 [2.50–10.52]

 Mean total OS

Weibull formula

15.95

9.40

6.55

OAK

Atezolizumab (112)

Docetaxel (110)

 RMS [95% CI]

to 24 mos

11.99 [10.37–13.62]

9.73 [8.31–11.14]

2.27 [0.11–4.42]

 Mean total OS

R_mSext

14.80

10.41

4.40

 Mean total OS

Weibull [95% CI]

14.34 [11.31–18.58]

10.26 [8.45–12.52]

4.08 [−0.09–8.25]

 Mean total OS

Weibull formula

14.34

10.25

4.09

Hanna

Pemetrexed (78)

Docetaxel (94)

 RMS [95% CI]

to 24 mos

NOT REACHED

 Mean total OS

R_mSext

7.40

8.83

−1.43 [−0.75–2.67]

 Mean total OS

Weibull [95% CI]

7.22 [5.95–8.75]

8.83 [7.32–10.59]

− 1.61 [−5.84–2.62]

 Mean total OS

Weibull formula

7.22

8.82

−1.61